TriMas Corp

TriMas Corp(TRS)股票分析

$39.300

-0.299 (-0.76%)收盤時

Loading chart…
最高
40.792
開盤
39.900
成交量加權均價
39.78
成交量
424.88K
市值
1.03B
最低
39.250
成交金額
16.90M
企業價值/稅息折舊攤銷前利潤(TTM)
5.98

TriMas Corporation designs, manufactures and supplies a range of products for the consumer packaging and industrial markets through its TriMas Packaging and Specialty Products groups. The Company's segments include Packaging and Specialty Products. Its Packaging segment offers dispensing, closure and flexible packaging solutions, including Rieke, Affaba & Ferrari, Taplast, Rapak and Aarts Packaging, along with Intertech and Omega Plastics, which provide life sciences–focused products. Its Packaging business develops and manufactures an array of dispensing products, polymeric and steel caps and closures, polymeric jar products, fully integrated dispensers for fill-ready bag-in-box applications, and consumable vascular delivery and diagnostic test components, all for a variety of consumer products submarkets. Its Specialty Products segment, which includes the Norris Cylinder business, designs, manufactures and distributes highly engineered steel cylinders.

AI 分析 of TriMas Corp (TRS)

買進

TriMas Corp (TRS) is a good buy right now due to its current price of 39.6, a strong RSI of 62.109 indicating bullish momentum, and a forward P/E ratio of 19.34 which suggests reasonable valuation compared to growth potential. Additionally, the company has shown a solid year-to-date change of +9.12%, reflecting positive market sentiment. However, a significant risk is the hedge fund selling activity, which has increased by 909.26% over the last quarter, indicating potential concerns among institutional investors.

分析師評級(6)

上檔空間 +5.60%
持有
1 買進
5 持有
0 賣出
目前: 39.30
最低
38.00
平均
41.50
最高
45.00

KeyBanc

2025-11-13

目標價

$38

增持

KeyBanc

2025-08-13

目標價

$45

增持

KeyBanc

2025-08-12

目標價

$45

增持

BWS Financial

2025-07-30

目標價

$45

買進

BWS Financial

2025-02-28

目標價

$40

強烈買進

估值指標

TriMas Corp(TRS)目前預期本益比為 19.34,5 年平均預期本益比為 15.05。

預期本益比

合理
5 年均值 P/E
15.05
目前P/E
19.34
高估
19.45
低估
10.65

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
8.47
目前EV/EBITDA
5.98
高估
11.43
低估
5.51

預期股價營收比

高估
5 年均值 P/S
1.36
目前P/S
2.05
高估
1.73
低估
0.99

Alphio AI 對 TRS 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%TRS

$24.42

情境價格

基

基準

基準 · 50%TRS

$23.53

情境價格

悲

悲觀

悲觀 · 25%TRS

$21.04

情境價格

持有 TRS 的大戶

J

Jefferies Financial Group Inc.

+ 持有TRS

+4.86%

3個月報酬率

A

Arthur J. Gallagher & Co.

+ 持有TRS

-11.14%

3個月報酬率

事件時間軸

2026-07-30 (ET)

08:30:00

Sees FY26 Sales Growth of 3%-6%

2026-04-30 (ET)

08:10:00

TriMas Reports Q1 Revenue of $168.28M

08:10:00

Company Reaffirms 2026 Sales Growth of 3%-6%

2026-03-16 (ET)

11:40:00

TriMas Completes Aerospace Divestiture for Approximately $1.45B

2026-02-26 (ET)

08:40:00

TriMas Q4 Revenue $155.49M, Below Consensus

資訊

TRS 常見問題 —— 由 Alphio AI 解答

TriMas Corporation designs, manufactures and supplies a range of products for the consumer packaging and industrial markets through its TriMas Packaging and Specialty Products groups. The Company's segments include Packaging and Specialty Products. Its Packaging segment offers dispensing, closure and flexible packaging solutions, including Rieke, Affaba & Ferrari, Taplast, Rapak and Aarts Packaging, along with Intertech and Omega Plastics, which provide life sciences–focused products. Its Packaging business develops and manufactures an array of dispensing products, polymeric and steel caps and closures, polymeric jar products, fully integrated dispensers for fill-ready bag-in-box applications, and consumable vascular delivery and diagnostic test components, all for a variety of consumer products submarkets. Its Specialty Products segment, which includes the Norris Cylinder business, designs, manufactures and distributes highly engineered steel cylinders. It operates in the Basic Materials sector (METAL FORGINGS & STAMPINGS industry).

TriMas Corp (TRS) is a good buy right now due to its current price of 39.6, a strong RSI of 62.109 indicating bullish momentum, and a forward P/E ratio of 19.34 which suggests reasonable valuation compared to growth potential. Additionally, the company has shown a solid year-to-date change of +9.12%, reflecting positive market sentiment. However, a significant risk is the hedge fund selling activity, which has increased by 909.26% over the last quarter, indicating potential concerns among institutional investors.

6 analysts cover TRS: 1 rate it Buy, 5 Hold and 0 Sell. The average price target is 41.50.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易